A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumor
Recurrent Solid Tumor
Advanced Solid Tumor
Urinary Bladder Neoplasm
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Renal Pelvis Cancer
Bladder Cancer

Interventions

DRUG: LY4052031

Sponsor

Eli Lilly and Company